ArticleBlood2025

Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.

Lindsey E Montefiori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.